US Pharma MarketingThe post J&J’s multiple myeloma combo cuts risk of death by 62% in Phase III study appeared first on Clinical Trials Arena.
J&J’s multiple myeloma combo cuts risk of death by 62% in Phase III study
J&J's MonumenTAL-6 results add to the growing body of evidence touting Talvey and Tecvayli’s use in earlier multiple myeloma treatment lines. The post J&J’s multiple myeloma combo cuts risk of death by 62% in Phase III study appeared first on Clinical Trials Arena .
J&J's MonumenTAL-6 results add to the growing body of evidence touting Talvey and Tecvayli’s use in earlier multiple myeloma treatment lines.
Source: Clinical Trials Arena